Grace Therapeutics, Inc. Common Stock GRCE
HEALTHCARE · BIOTECHNOLOGYi
Market datapartial · fetched 2026-11-04T00:30:19.299Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.590934639Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T00:30:18.097389+00:00
Grace Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 2.55 | 499.6% | 55.4% | |||
| 30Δ | 2.78 | 475.0% | 50.8% | |||
| 35Δ | 3.00 | 450.3% | 46.2% | |||
| 40Δ | 3.22 | 425.6% | 41.7% | |||
| 45Δ | 3.44 | 401.0% | 37.1% | |||
| 50Δ | 3.66 | 376.3% | 32.5% | |||
| 55Δ | 3.89 | 351.7% | 27.9% | |||
| 60Δ | 4.11 | 327.0% | 23.3% | |||
| 65Δ | 4.33 | 302.3% | 18.7% | |||
| 70Δ | 4.55 | 277.7% | 14.1% | |||
| 75Δ | 4.78 | 253.0% | 9.5% | |||
| 80Δ | 5.00 | 228.4% | 4.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.55
- IV
- 499.6%
- B/E move
- 55.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.78
- IV
- 475.0%
- B/E move
- 50.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.00
- IV
- 450.3%
- B/E move
- 46.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.22
- IV
- 425.6%
- B/E move
- 41.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.44
- IV
- 401.0%
- B/E move
- 37.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.66
- IV
- 376.3%
- B/E move
- 32.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.89
- IV
- 351.7%
- B/E move
- 27.9%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.11
- IV
- 327.0%
- B/E move
- 23.3%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.33
- IV
- 302.3%
- B/E move
- 18.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.55
- IV
- 277.7%
- B/E move
- 14.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.78
- IV
- 253.0%
- B/E move
- 9.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.00
- IV
- 228.4%
- B/E move
- 4.9%
Options history
No recorded observations
Biotechnology
GYRE
Description unavailable
More →HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is…
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Description unavailable
More →